New England Journal of Medicine· 2017Q1

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar et al.

3,209citations
Q1SCImago
2017year

Short summary

<sup>177</sup>Lu-Dotatate significantly improved progression-free survival (PFS) in patients with advanced midgut neuroendocrine tumors, extending it to a median of 40.2 months versus 10.8 months with octreotide LAR alone (hazard ratio for progression or death, 0.21).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Epidemiology

EpidemiologyMedicine